# Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct07181161/  
OnCo record `nct07181161` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Palacaparib in prostate cancer, run by AstraZeneca, now recruiting.

## Summary

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07181161 by AstraZeneca, with 283 participants planned, started 2025-10-01 and due to reach its primary completion in 2029-01-18. Interventions recorded: AZD0516, AZD9574. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07181161
- Phase: 1/2
- Setting: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer
- Sponsor: AstraZeneca
- Enrolled: 283

## Sources

- ClinicalTrials.gov NCT07181161: https://clinicaltrials.gov/study/NCT07181161

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Palacaparib](https://onco.cc/drugs/palacaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07181161.json